Fangjian Zhou

Sun Yat-sen University — China

Medicine · Health Sciences

35h-index5.8kcitations265works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(90), Bladder and Urothelial Cancer Treatments(80), Cancer Immunotherapy and Biomarkers(52), Prostate Cancer Treatment and Research(34), Epigenetics and DNA Methylation(33)

Publications265 total

Functional and volumetric changes following partial nephrectomy for large (≥7 cm) renal masses: A comparative study
2025Open Access
Synthetic Code Mixing for StyleGAN Image Manipulation
2025
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma: Subgroup analysis from the phase 3 ETER100 trial.
Journal of Clinical Oncology·2025
Efficacy and safety of modified bleomycin administration with EP chemotherapy in adult male patients with germ cell tumors: a retrospective study
Cancer Cell International·2025· 3 citedOpen Access
Malignant adenomyoepithelioma of the breast with axillary lymph node metastasis: a case report and review of the literature
Frontiers in Oncology·2025· 1 citedOpen Access
The role of IL-33 in immunotherapy for breast cancer: targets and signalling pathways
European Cytokine Network·2025
A0765 – Efficacy and safety of neoadjuvant pazopanib plus sintilimab in renal cell carcinoma patients with high surgical complexity of partial nephrectomy: A phase II trial
European Urology·2025
Response evaluation and tumor shrinkage pattern post-SBRT for renal cell carcinoma
Radiotherapy and Oncology·2025· 2 citedOpen Access
Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1/2 MK-2870-001 study.
Journal of Clinical Oncology·2025· 10 cited
Impact of adjuvant intraarterial chemotherapy on survival for patients with stage IIIA-IIIB bladder urothelial carcinoma after radical cystectomy: An open-label, prospective, randomized clinical trial.
Journal of Clinical Oncology·2025
A phase II clinical study of camrelizumab plus apatinib in combination with stereotactic body radiotherapy (SBRT) for advanced non-clear cell renal cell carcinoma (nccRCC).
Journal of Clinical Oncology·2025
Clinical characteristics and prognostic factors of low metastatic burden prostate cancer with non-regional lymph node metastases: role of cytoreductive radiotherapy?
Translational Andrology and Urology·2025Open Access
Can parenchymal volume analysis replace nuclear renal scans for split renal function before and after partial nephrectomy with warm ischemia?
Urologic Oncology Seminars and Original Investigations·2025· 3 cited
Multi-Scale Hashing with Channel Attention and Regularization Via Integrated Hash Centers for Agricultural Pest Retrieval
SSRN Electronic Journal·2025Open Access
107P Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Immuno-Oncology Technology·2024Open Access
SARS-CoV-2 nucleocapsid protein interaction with YBX1 displays oncolytic properties through PKM mRNA destabilization
Molecular Cancer·2024· 9 citedOpen Access
China ARCHES: A Phase 3 Trial of Enzalutamide vs Placebo in Metastatic Hormone-Sensitive Prostate Cancer
JU Open Plus·2024· 2 citedOpen Access
EP.06E.03 Body Composition and Inflammation Index-Based Nomograms to Assess the Outcomes of Patients with NSCLC Receiving Chemoimmunotherapy
Journal of Thoracic Oncology·2024Open Access
LBA76 Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC): A randomized, open-label, phase III study (ETER100)
Annals of Oncology·2024· 6 citedOpen Access
A multi-classifier system integrated by clinico-histology-genomic analysis for predicting recurrence of papillary renal cell carcinoma
Nature Communications·2024· 16 citedOpen Access
page 1 of 14Next →

Frequent Co-authors

Zhiling Zhang(15), Zhuowei Liu(13), Song Wu(10), Zhiming Cai(9), Pei Dong(8), Yaoting Gui(6), Chang Yin Liang(6), Shengjie Guo(6), Chunping Yu(6), Zike Qin(6), Hui Han(6), Aifa Tang(5), Xiaojuan Sun(5), Zhimao Jiang(5), Huanming Yang(5), Junhang Luo(5), Dan Xie(5), Zhiwen Chen(5), Dalin He(5), Yinghao Sun(5)